Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials
Open Access
- 1 January 2021
- journal article
- review article
- Published by Wiley in European Journal of Heart Failure
- Vol. 23 (1), 92-113
- https://doi.org/10.1002/ejhf.1838
Abstract
Endpoints of large-scale trials in chronic heart failure have mostly been defined to evaluate treatments with regard to hospitalizations and mortality. However, patients with heart failure are also affected by very severe reductions in exercise capacity and quality of life. We aimed to evaluate the effects of heart failure treatments on these endpoints using available evidence from randomized trials. Interventions with evidence for improvements in exercise capacity include physical exercise, intravenous iron supplementation in patients with iron deficiency, and - with less certainty - testosterone in highly selected patients. Erythropoiesis-stimulating agents have been reported to improve exercise capacity in anaemic patients with heart failure. Sinus rhythm may have some advantage when compared with atrial fibrillation, particularly in patients undergoing pulmonary vein isolation. Studies assessing treatments for heart failure co-morbidities such as sleep-disordered breathing, diabetes mellitus, chronic kidney disease and depression have reported improvements of exercise capacity and quality of life; however, the available data are limited and not always consistent. The available evidence for positive effects of pharmacologic interventions using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists on exercise capacity and quality of life is limited. Studies with ivabradine and with sacubitril/valsartan suggest beneficial effects at improving quality of life; however, the evidence base is limited in particular for exercise capacity. The data for heart failure with preserved ejection fraction are even less positive, only sacubitril/valsartan and spironolactone have shown some effectiveness at improving quality of life. In conclusion, the evidence for state-of-the-art heart failure treatments with regard to exercise capacity and quality of life is limited and appears not robust enough to permit recommendations for heart failure. The treatment of co-morbidities may be important for these patient-related outcomes. Additional studies on functional capacity and quality of life in heart failure are required.This publication has 144 references indexed in Scilit:
- Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD studyEuropean Journal of Heart Failure, 2012
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAmerican Heart Journal, 2011
- Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing DiureticsThe Journal of Clinical Hypertension, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Exercise Training in Older Patients With Heart Failure and Preserved Ejection FractionCirculation: Heart Failure, 2010
- Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humansJournal Of Physiology-London, 2010
- Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) TrialJournal of the American College of Cardiology, 2010
- Effects of Exercise Training on Health Status in Patients With Chronic Heart FailureJAMA, 2009
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionThe New England Journal of Medicine, 1999